Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formaldehyde SCHEMBL28513707 | 0.96 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL2540267 | 0.90 | ALDH1A1 (0.44) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL16746570 | 0.89 | ALDH1A1 (0.53) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL14483861 | 0.84 | ALDH1A1 (0.53) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL12228653 | 0.84 | RXRA (0.42) | ALDH1A1TDP1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL1680118 | 0.84 | ALDH1A1 (0.56) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL28281565 | 0.83 | ALDH1A1 (0.45) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL15514064 | 0.82 | SYK (0.53) | ALDH1A1SYKSMN1; SMN2CA12CA1 | |
| SCHEMBL20033375 | 0.82 | SYK (0.44) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL19452722 | 0.82 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362436-B1 | PROCESS FOR THE CATALYTIC DIRECTED CLEAVAGE OF AMIDE-CONTAINING COMPOUNDS | UNIV ANTWERPEN (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-10654834-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2019-10-31 | — | — | US | disclosed |
| US-10320030-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-11 | — | — | US | disclosed |
| US-20150140448-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2869389-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | Mitsubishi Chemical Corporation (JP) | 2015-05-06 | — | — | EP | disclosed |
| EP-1154980-B1 | METHOD FOR PRODUCING SYMMETRICAL AND ASYMMETRICAL CARBONATES | GOEDECKE GMBH (DE) | 2004-05-26 | — | — | EP | disclosed |
| US-6740768-B1 | REACTING ALKYL OR ARYL ALCOHOL AND HALIDE WITH CARBON DIOXIDE AND CESIUM CARBONATE AT ROOM TEMPERATURE IN DIPOLAR APROTIC SOLVENT | GOEDECKE GMBH (DE) | 2004-05-25 | — | — | US | disclosed |
| EP-1154980-A1 | METHOD FOR PRODUCING SYMMETRICAL AND ASYMMETRICAL CARBONATES | GÖDECKE GMBH (DE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047544-A1 | METHOD FOR PRODUCING SYMMETRICAL AND ASYMMETRICAL CARBONATES | Gödecke GmbH (DE) | 2000-08-17 | — | — | WO | disclosed |
| CN-1261276-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2000-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, FFAR1, FFAR3 | ALDH1A1 3170/4885TDP1 2685/4885MAPK1 1710/4885 |
| US-10654834-B2 | Non-systemic TGR5 agonists | GPR119, SSTR5, FFAR3 | ALDH1A1 3118/4885TDP1 2492/4885MAPK1 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.